STOP Persistent AF PAS

Description

The STOP Persistent AF Post Approval Study (PAS) is a prospective, global, multicenter, observational trial.

Conditions

Persistent Atrial Fibrillation

Talk to us

Study Overview

On this page

Study Details

Study overview

The STOP Persistent AF Post Approval Study (PAS) is a prospective, global, multicenter, observational trial.

STOP Persistent AF Post-Approval Study, a Sub-study to the Cryo Global Registry

STOP Persistent AF PAS

Condition
Persistent Atrial Fibrillation
Intervention / Treatment

-

Contacts and Locations

Hartford

Hartford Hospital, Hartford, Connecticut, United States, 06102

Stamford

Cardiology Associates of Fairfield County, Stamford, Connecticut, United States, 06905-5522

Clearwater

BayCare Medical Group Cardiology, Clearwater, Florida, United States, 33756

Davie

Heart Rhythms Solutions, Davie, Florida, United States, 33328

Urbana

Carle Foundation Hospital, Urbana, Illinois, United States, 61801-2500

Detroit

Henry Ford Heart & Vascular, Detroit, Michigan, United States, 48202-2608

Grand Rapids

Spectrum Health Hospitals, Grand Rapids, Michigan, United States, 49525-6427

Cincinnati

The Lindner Research Center, Cincinnati, Ohio, United States, 45219-2906

Austin

Texas Cardiac Arrhythmia Research Foundation, Austin, Texas, United States, 78705-1852

Dallas

Texas Health Research & Education Institute, Dallas, Texas, United States, 75231

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Subject has been diagnosed with persistent AF.
  • * Subject is ≥ 18 years of age or minimum age as required by local regulations.
  • * Planned pulmonary vein isolation (PVI) procedure using commercially available Arctic Front™ Cardiac Cryoablation Catheter System.
  • * Willing to comply with study requirements and give informed consent (defined as legally effective, documented confirmation of a subject's voluntary agreement to participate in this clinical study) or authorization per institution and geographical requirements.
  • * Subject has had a prior atrial ablation (except for cavo-tricuspid isthmus (CTI) ablation for AFL).
  • * Subject is enrolled in a concurrent study that has not been approved for concurrent enrollment by the global study manager.
  • * Subject with exclusion criteria required by local law.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Medtronic Cardiac Rhythm and Heart Failure,

Khaldoun Tarakji, MD, STUDY_DIRECTOR, Medtronic CAS Chief Medical Officer

Study Record Dates

2027-08